Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release

Micelles are colloidal particles with a size around 5–100 nm which are currently under investigation as carriers for hydrophobic drugs in anticancer therapy. Currently, five micellar formulations for anticancer therapy are under clinical evaluation, of which Genexol-PM has been FDA approved for use in patients with breast cancer. Micelle-based drug delivery, however, can be improved in different ways. Targeting ligands can be attached to the micelles which specifically recognize and bind to receptors overexpressed in tumor cells, and chelation or incorporation of imaging moieties enables tracking micelles in vivo for biodistribution studies. Moreover, pH-, thermo-, ultrasound-, or light-sensitive block copolymers allow for controlled micelle dissociation and triggered drug release. The combination of these approaches will further improve specificity and efficacy of micelle-based drug delivery and brings the development of a ‘magic bullet’ a major step forward

Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors

Over recent years, multifunctional compounds that combine diagnostic and therapeutic modalities using one unified material have been developed and designated as theranostics. These compounds provide the chance to develop individually designed therapies against various diseases to accomplish personalized medicine. In this review, theranostic agents based on nanovectors (liposomes, naposomes, micelles, polymeric micelles and micelles built around a solid core) externally modified with targeting peptides able to simultaneously carry a drug and a contrast agent are described, demonstrating that peptide-modified nanovectors can selectively carry a drug to target cells with an imaging probe co-incorporated into the nanovector to monitor therapy